Empagliflozin to prevent post-operative atrial fibrillation in patients undergoing coronary artery bypass graft surgery: Rationale and design of the EMPOAF trial.
Maryam AghakouchakzadehKaveh HosseiniHamidreza FallahParastoo MirzabeigiMasih TajdiniAzita H TalasazArash JalaliAmir AskarinejadErfan KohansalBehnam HedayatEhsan ParvasAli BozorgiJamshid BagheriNader GivtajNaser HadavandAlireza HajighasemiSeyed Hossein Ahmadi TaftiSaeid HosseiniParham SadeghipourHessam KakavandPublished in: Pacing and clinical electrophysiology : PACE (2024)
EMPOAF will prospectively evaluate whether empagliflozin 10 mg daily can reduce the rate of POAF in patients undergoing elective CABG. Enrolment into this study has started by November 2023 and is expected to be ended before the end of 2025.
Keyphrases
- coronary artery bypass
- patients undergoing
- percutaneous coronary intervention
- atrial fibrillation
- clinical trial
- acute coronary syndrome
- coronary artery disease
- heart failure
- phase iii
- study protocol
- coronary artery bypass grafting
- physical activity
- health insurance
- randomized controlled trial
- left atrial
- minimally invasive
- phase ii
- catheter ablation
- direct oral anticoagulants
- venous thromboembolism